How many FDA actions has HISUN PHARM HANGZHOU had?

Argus HQ has recorded 1 FDA events for HISUN PHARM HANGZHOU: 0 warning letters, 0 recalls, 1 approvals, and 0 Form 483 inspection observations. Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures.

What is the most recent FDA action against HISUN PHARM HANGZHOU?

The most recent FDA event Argus HQ has on file for HISUN PHARM HANGZHOU is dated 2026-07-23, with a severity rating of "info" in Argus HQ's classification. Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures.

Does Argus HQ track new FDA actions for HISUN PHARM HANGZHOU automatically?

Yes. Argus HQ ingests FDA sources daily, including FDA warning letters, recalls, drug and biologic approvals, and Form 483 inspection observations. When a new FDA action linked to HISUN PHARM HANGZHOU is observed, this page's event count and history update automatically.

How many FDA actions does Argus HQ track for HISUN PHARM HANGZHOU?

1 total: 0 warning letters, 0 recalls, 1 approval record, and 0 Form 483 inspection citations.

FDA Enforcement History: HISUN PHARM HANGZHOU

Here's the summary: Argus HQ has recorded 1 FDA events for HISUN PHARM HANGZHOU: 0 warning letters, 0 recalls, 1 approvals, and 0 inspection 483 observations. These events span from 2026-07-23 to 2026-07-23. The most severe rating Argus HQ has assigned across this history is "info". Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures. This page reflects only the FDA event types Argus HQ currently tracks -- FDA Warning Letters, recalls, drug and biologic approvals, and Form 483 inspection observations -- and will update automatically as new FDA records are observed. Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures. This page reflects only the FDA event types Argus HQ currently tracks -- FDA Warning Letters, recalls, drug and biologic approvals, and Form 483 inspection observations -- and will update automatically as new FDA records are observed.

FDA action counts

Total FDA actions	1
Warning letters	0
Recalls	0
Approval records	1
Form 483 inspection citations	0
Most recent action	July 23, 2026

Risk pattern analysis

Argus HQ analysis — not an FDA finding

This section is Argus HQ analysis, not an FDA finding. HISUN PHARM HANGZHOU has 1 FDA event on file. A pattern across multiple FDA touchpoints does not by itself establish that any specific product currently poses a risk; it reflects only the frequency of FDA engagement with this company as recorded in Argus HQ's database. Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures. This page reflects only the FDA event types Argus HQ currently tracks -- FDA Warning Letters, recalls, drug and biologic approvals, and Form 483 inspection observations -- and will update automatically as new FDA records are observed. Argus HQ does not independently verify FDA's underlying findings; this page summarizes what FDA has published and links back to the original FDA source for each event. Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures.

Enforcement history

On 2026-07-23, Argus HQ recorded an FDA approval for HISUN PHARM HANGZHOU, rated "info" severity in Argus HQ's classification: HISUN PHARM HANGZHOU — ANDA approval: FLUDARABINE PHOSPHATE (unspecified). Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures. This page reflects only the FDA event types Argus HQ currently tracks -- FDA Warning Letters, recalls, drug and biologic approvals, and Form 483 inspection observations -- and will update automatically as new FDA records are observed. Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures. This page reflects only the FDA event types Argus HQ currently tracks -- FDA Warning Letters, recalls, drug and biologic approvals, and Form 483 inspection observations -- and will update automatically as new FDA records are observed. Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures. This page reflects only the FDA event types Argus HQ currently tracks -- FDA Warning Letters, recalls, drug and biologic approvals, and Form 483 inspection observations -- and will update automatically as new FDA records are observed. Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures. This page reflects only the FDA event types Argus HQ currently tracks -- FDA Warning Letters, recalls, drug and biologic approvals, and Form 483 inspection observations -- and will update automatically as new FDA records are observed.

Frequently asked questions

How many FDA actions has HISUN PHARM HANGZHOU had?: Argus HQ has recorded 1 FDA events for HISUN PHARM HANGZHOU: 0 warning letters, 0 recalls, 1 approvals, and 0 Form 483 inspection observations. Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures.
What is the most recent FDA action against HISUN PHARM HANGZHOU?: The most recent FDA event Argus HQ has on file for HISUN PHARM HANGZHOU is dated 2026-07-23, with a severity rating of "info" in Argus HQ's classification. Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures.
Does Argus HQ track new FDA actions for HISUN PHARM HANGZHOU automatically?: Yes. Argus HQ ingests FDA sources daily, including FDA warning letters, recalls, drug and biologic approvals, and Form 483 inspection observations. When a new FDA action linked to HISUN PHARM HANGZHOU is observed, this page's event count and history update automatically.
How many FDA actions does Argus HQ track for HISUN PHARM HANGZHOU?: 1 total: 0 warning letters, 0 recalls, 1 approval record, and 0 Form 483 inspection citations.

Every FDA action tied to this company, the week it happens.

Free weekly briefing. Real-time alerts on paid plans.

HISUN PHARM HANGZHOU — ANDA approval: FLUDARABINE PHOSPHATE (unspecified) →

Compare with

Two different companies merged onto this page by mistake? Or a name variant missing? Tell us — corrections@argushq.ai

Compiled by Argus HQ Research from FDA primary sources · Reviewed by Andy Gaber, Founder

Verified from FDA.gov · Last updated: Jul 23, 2026

Cite this record

Reusing this data in reporting or research? Here’s a ready-made citation.

APA

Argus HQ Research (2026). FDA Enforcement History: HISUN PHARM HANGZHOU. Digital Empire Holdings LLC. Retrieved from https://argushq.ai/company/hisun-pharm-hangzhou

MLA

"FDA Enforcement History: HISUN PHARM HANGZHOU." Argus HQ Research, Digital Empire Holdings LLC, 2026, argushq.ai/company/hisun-pharm-hangzhou.

Chicago

Argus HQ Research. "FDA Enforcement History: HISUN PHARM HANGZHOU." Digital Empire Holdings LLC. Accessed July 29, 2026. https://argushq.ai/company/hisun-pharm-hangzhou.

BibTeX

@misc{argushq_argushq_ai_company_hisun_pharm_hangzhou_2026,
  title = {FDA Enforcement History: HISUN PHARM HANGZHOU},
  author = {{Argus HQ Research}},
  year = {2026},
  publisher = {Digital Empire Holdings LLC},
  url = {https://argushq.ai/company/hisun-pharm-hangzhou},
  note = {Accessed: July 29, 2026}
}

Source: FDA.gov (aggregated across Warning Letters, Recalls, Approvals, Form 483s) ↗